The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...

Plaque PsO is an immune-mediated disease resulting in the overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. It is estimated that eight million Americans ...

The National Psoriasis Foundation issued a new position statement that clarifies the definition of psoriasis disease severity ...

Guselkumab significantly and rapidly improved severe scalp psoriasis, itch, and patient-reported health-related quality of life outcomes in people of color. Guselkumab shows rapid and significant ...

Please provide your email address to receive an email when new articles are posted on . At week 16, 49.4% of the tildrakizumab group achieved clearance or near clearance of their scalp psoriasis vs. 7 ...

Response rates were greater with deucravacitinib vs placebo or apremilast at 16 weeks in patients with moderate to severe scalp psoriasis, according to one study. In a study comparing deucravacitinib ...

Deucravacitinib was safe and effective for treating moderate to severe scalp psoriasis over 16 weeks, even among patients with less extensive overall disease. Deucravacitinib demonstrates significant ...

Tildrakizumab was well tolerated and achieved sustained response in patients with moderate to severe plaque psoriasis of the scalp in a phase 3 study. This study excluded patients with predominantly ...

Otezla (apremilast) is an oral tablet commonly used to treat plaque psoriasis in adults and children. Plaque psoriasis is an inflammatory skin condition that causes itchy, painful patches on the skin.

While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...